Symbols / QCLS Stock $3.82 -3.52% Q/C Technologies, Inc.

Technology • Computer Hardware • United States • NCM
QCLS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Technology
Industry Computer Hardware
CEO —
Exch · Country NCM · United States
Market Cap 30.01M
Enterprise Value 18.41M
Income -14.98M
Sales —
FCF (ttm) -6.86M
Book/sh 2.81
Cash/sh 2.01
Employees 2
Insider 10d —
IPO Jan 23, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E —
PEG —
P/S —
P/B 1.36
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 2.86
Current Ratio 3.00
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -8.66
EPS next Y —
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) —
Earnings (prior) —
ROA -19.14%
ROE -58.95%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 7.85M
Shs Float 7.43M
Insider Own 4.35%
Instit Own 5.33%
Short Float 17.35%
Short Ratio 2.57
Short Interest 1.30M
52W High 33.60
vs 52W High -88.63%
52W Low 2.50
vs 52W Low 52.83%
Beta 2.15
Impl. Vol. —
Rel Volume 0.41
Avg Volume 614.64K
Volume 249.66K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $3.96
Price $3.82
Change -3.52%
About

Q/C Technologies, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog of derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. The company also develops a silicon photonic computing architecture for AI inference. The company has a strategic alliance with DADA2 Foundation for research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2). The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$3.82
Latest analyst target
3. DCF / Fair value
$-15.73
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.82
Low
—
High
—
Mean
—
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-16 VOSS CHELSEA SIERRA Director — 237,500 $0.00 $0
2025-11-14 BERNSTEIN BRUCE G Director — 25,000 $0.00 $0
2025-11-14 WHITE BILLY JOE Director — 22,839 $0.00 $0
2025-11-14 RAUCH GARY M Divisional Officer — 11,420 $0.00 $0
2025-11-14 GLASS MITCHELL Officer and Director — 11,420 $0.00 $0
2025-11-14 FRISCIA STEPHEN Director — 22,839 $0.00 $0
2025-10-03 WHITE BILLY JOE Director — 2,161 $0.00 $0
2025-10-03 RAUCH GARY M Divisional Officer — 1,080 $0.00 $0
2025-10-03 GLASS MITCHELL Officer and Director — 1,080 $0.00 $0
2025-10-03 FRISCIA STEPHEN Director — 2,161 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Cost Of Revenue
0.00
0.00
0.00
0.00
Reconciled Cost Of Revenue
0.00
0.00
0.00
0.00
Gross Profit
0.00
0.00
0.00
0.00
Operating Expense
9.58
+10.66%
8.66
-47.07%
16.36
+7.05%
15.28
Research And Development
3.47
+0.90%
3.44
-56.26%
7.87
-13.23%
9.07
Selling General And Administration
5.91
+13.26%
5.22
-38.54%
8.49
+36.64%
6.22
General And Administrative Expense
5.91
+13.26%
5.22
-38.54%
8.49
+36.64%
6.22
Salaries And Wages
2.56
+49.56%
1.71
-61.70%
4.46
+139.25%
1.86
Other Gand A
3.36
-4.41%
3.51
-12.93%
4.03
-7.33%
4.35
Other Operating Expenses
—
1.51
—
—
Total Expenses
9.58
+10.66%
8.66
-47.07%
16.36
+7.05%
15.28
Operating Income
-9.58
-10.66%
-8.66
+47.07%
-16.36
-7.05%
-15.28
Total Operating Income As Reported
-9.85
+3.16%
-10.17
+40.61%
-17.12
-12.04%
-15.28
EBITDA
-9.58
-10.66%
-8.66
+47.07%
-16.36
-7.05%
-15.28
Normalized EBITDA
-7.58
-91.17%
-3.96
+86.34%
-29.03
-89.92%
-15.28
Reconciled Depreciation
—
—
—
—
EBIT
-9.58
-10.66%
-8.66
+47.07%
-16.36
-7.05%
-15.28
Total Unusual Items
-2.01
+57.30%
-4.70
-137.07%
12.67
+882040.11%
0.00
Total Unusual Items Excluding Goodwill
-2.01
+57.30%
-4.70
-137.07%
12.67
+882040.11%
0.00
Special Income Charges
-3.03
-3129.00%
0.10
+156.12%
-0.18
-4111.66%
0.00
Other Special Charges
—
-0.10
-156.12%
0.18
+4111.66%
-0.00
Restructuring And Mergern Acquisition
1.53
—
—
—
Write Off
1.50
0.00
—
—
Net Income
-11.63
+50.22%
-23.36
-483.99%
-4.00
+73.68%
-15.20
Pretax Income
-11.63
+50.22%
-23.36
-483.99%
-4.00
+73.68%
-15.20
Net Non Operating Interest Income Expense
0.23
-35.93%
0.35
-22.78%
0.46
+442.40%
0.08
Interest Expense Non Operating
—
—
—
0.00
Net Interest Income
0.23
-35.93%
0.35
-22.78%
0.46
+442.40%
0.08
Interest Expense
—
—
—
0.00
Interest Income Non Operating
0.23
-35.93%
0.35
-22.78%
0.46
+442.40%
0.08
Interest Income
0.23
-35.93%
0.35
-22.78%
0.46
+442.40%
0.08
Other Income Expense
-2.27
+84.92%
-15.05
-226.43%
11.90
+828917.97%
0.00
Other Non Operating Income Expenses
-0.26
+97.45%
-10.35
-1257.39%
-0.76
—
Gain On Sale Of Security
1.02
+121.35%
-4.80
-137.34%
12.85
+427436.33%
-0.00
Tax Provision
0.00
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-11.63
+50.22%
-23.36
-483.99%
-4.00
+73.68%
-15.20
Net Income From Continuing Operation Net Minority Interest
-11.63
+50.22%
-23.36
-483.99%
-4.00
+73.68%
-15.20
Net Income From Continuing And Discontinued Operation
-11.63
+50.22%
-23.36
-483.99%
-4.00
+73.68%
-15.20
Net Income Continuous Operations
-11.63
+50.22%
-23.36
-483.99%
-4.00
+73.68%
-15.20
Normalized Income
-9.62
+48.44%
-18.66
-11.97%
-16.67
-9.66%
-15.20
Net Income Common Stockholders
-14.98
+44.83%
-27.16
-230.50%
-8.22
+45.92%
-15.20
Diluted EPS
—
-1,080.87
-102.79%
-533.00
+54.60%
-1,174.00
Basic EPS
—
-1,080.87
-102.79%
-533.00
+54.60%
-1,174.00
Basic Average Shares
—
0.03
+62.92%
0.02
+19.19%
0.01
Diluted Average Shares
—
0.03
+62.92%
0.02
+19.19%
0.01
Diluted NI Availto Com Stockholders
-14.98
+44.83%
-27.16
-230.50%
-8.22
+45.92%
-15.20
Amortization
—
—
—
—
Amortization Of Intangibles Income Statement
—
—
—
—
Depreciation Amortization Depletion Income Statement
—
—
—
—
Depreciation And Amortization In Income Statement
—
—
—
—
Other Taxes
0.20
0.00
—
—
Preferred Stock Dividends
3.36
-11.69%
3.80
-9.87%
4.22
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
41.17
+92.18%
21.42
+19.92%
17.86
+1.84%
17.54
Current Assets
16.58
+76.16%
9.41
+61.82%
5.82
+7.67%
5.40
Cash Cash Equivalents And Short Term Investments
15.79
+85.35%
8.52
+73.03%
4.92
+1.80%
4.84
Cash And Cash Equivalents
0.99
+470.01%
0.17
-93.54%
2.68
+257.90%
0.75
Cash Financial
0.99
+470.01%
0.17
-93.54%
2.68
—
Other Short Term Investments
14.80
+77.37%
8.35
+272.20%
2.24
-45.14%
4.09
Receivables
0.02
0.00
—
—
Other Receivables
0.02
—
—
—
Prepaid Assets
0.77
-13.39%
0.89
+0.06%
0.89
+57.87%
0.57
Total Non Current Assets
24.59
+104.72%
12.01
-0.31%
12.05
-0.76%
12.14
Net PPE
0.00
-100.00%
0.01
-77.68%
0.05
-66.07%
0.14
Gross PPE
0.00
-100.00%
0.01
-77.68%
0.05
-66.07%
0.14
Machinery Furniture Equipment
0.00
-100.00%
0.01
-77.68%
0.05
-66.07%
0.14
Other Properties
—
—
0.05
-66.07%
0.14
Goodwill And Other Intangible Assets
24.59
+134.18%
10.50
+0.00%
10.50
+0.00%
10.50
Goodwill
10.50
+0.00%
10.50
+0.00%
10.50
+0.00%
10.50
Other Intangible Assets
14.09
—
—
—
Investments And Advances
0.00
-100.00%
1.50
+0.00%
1.50
+0.00%
1.50
Long Term Equity Investment
0.00
-100.00%
1.50
+0.00%
1.50
+0.00%
1.50
Total Liabilities Net Minority Interest
19.41
+66.91%
11.63
+111.76%
5.49
+93.07%
2.84
Current Liabilities
5.53
-17.45%
6.70
+34.35%
4.99
+80.14%
2.77
Payables And Accrued Expenses
3.39
-37.17%
5.39
+34.32%
4.01
+48.39%
2.70
Payables
3.00
-39.97%
5.00
+48.22%
3.37
+41.38%
2.39
Accounts Payable
2.07
-17.61%
2.52
-18.31%
3.08
+30.66%
2.36
Other Payable
0.53
—
—
—
Dividends Payable
0.37
-85.10%
2.46
+826.60%
0.27
0.00
Current Accrued Expenses
0.38
-0.95%
0.39
-39.31%
0.64
+101.20%
0.32
Current Debt And Capital Lease Obligation
—
0.01
-78.35%
0.05
-25.71%
0.07
Current Capital Lease Obligation
0.00
-100.00%
0.01
-78.35%
0.05
-25.71%
0.07
Other Current Liabilities
2.15
+64.77%
1.30
+40.41%
0.93
—
Total Non Current Liabilities Net Minority Interest
13.88
+181.59%
4.93
+876.99%
0.50
+564.48%
0.08
Long Term Debt And Capital Lease Obligation
—
—
0.00
-100.00%
0.08
Long Term Capital Lease Obligation
—
—
0.00
-100.00%
0.08
Tradeand Other Payables Non Current
10.91
0.00
-100.00%
0.10
0.00
Non Current Deferred Liabilities
—
—
0.10
0.00
Preferred Securities Outside Stock Equity
2.97
-39.69%
4.93
+1120.08%
0.40
0.00
Stockholders Equity
21.75
+122.19%
9.79
-20.86%
12.37
-15.82%
14.70
Common Stock Equity
21.61
+124.02%
9.65
-21.10%
12.23
-15.98%
14.55
Capital Stock
0.33
+122.48%
0.15
+0.92%
0.15
+0.48%
0.15
Common Stock
0.18
+5384.60%
0.00
+66.62%
0.00
+53.42%
0.00
Preferred Stock
0.14
+0.00%
0.14
+0.00%
0.14
+0.00%
0.14
Share Issued
7.69
+22763.61%
0.03
+66.61%
0.02
+53.45%
0.01
Ordinary Shares Number
7.69
+22763.61%
0.03
+66.61%
0.02
+53.45%
0.01
Additional Paid In Capital
165.55
+19.29%
138.78
+21.52%
114.20
+5.44%
108.31
Retained Earnings
-144.12
-11.60%
-129.14
-26.63%
-101.98
-8.77%
-93.76
Total Equity Gross Minority Interest
21.75
+122.19%
9.79
-20.86%
12.37
-15.82%
14.70
Total Capitalization
21.75
+122.19%
9.79
-20.86%
12.37
-15.82%
14.70
Working Capital
11.05
+307.60%
2.71
+227.27%
0.83
-68.54%
2.63
Invested Capital
21.61
+124.02%
9.65
-21.10%
12.23
-15.98%
14.55
Total Debt
0.00
-100.00%
0.01
-78.35%
0.05
-65.52%
0.14
Capital Lease Obligations
0.00
-100.00%
0.01
-78.35%
0.05
-65.52%
0.14
Net Tangible Assets
-2.83
-299.81%
-0.71
-137.88%
1.87
-55.41%
4.20
Tangible Book Value
-2.98
-249.03%
-0.85
-149.42%
1.73
-57.39%
4.05
Dueto Related Parties Current
0.03
+0.00%
0.03
+0.00%
0.03
+0.00%
0.03
Dueto Related Parties Non Current
—
—
—
0.00
Interest Payable
—
—
—
—
Investmentsin Subsidiariesat Cost
0.00
-100.00%
1.50
+0.00%
1.50
+0.00%
1.50
Line Of Credit
—
—
—
—
Preferred Shares Number
0.07
+0.00%
0.07
+0.00%
0.07
+0.00%
0.07
Preferred Stock Equity
0.14
+0.00%
0.14
+0.00%
0.14
+0.00%
0.14
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-9.07
-0.99%
-8.98
+30.85%
-12.98
-5.79%
-12.27
Cash Flow From Continuing Operating Activities
-9.07
-0.99%
-8.98
+30.85%
-12.98
-5.79%
-12.27
Net Income From Continuing Operations
-11.63
+50.22%
-23.36
-483.99%
-4.00
+73.68%
-15.20
Depreciation Amortization Depletion
—
—
—
—
Amortization Cash Flow
—
—
—
—
Depreciation And Amortization
—
—
—
—
Amortization Of Intangibles
—
—
—
—
Other Non Cash Items
1.53
-82.72%
8.85
—
0.25
Stock Based Compensation
2.17
+31.21%
1.66
-45.65%
3.05
+338.66%
0.70
Asset Impairment Charge
1.50
0.00
—
—
Operating Gains Losses
-0.99
-120.54%
4.80
+137.34%
-12.85
-215479.21%
0.01
Gain Loss On Investment Securities
-0.99
-120.54%
4.80
+137.34%
-12.85
-215479.21%
0.01
Unrealized Gain Loss On Investment Securities
-0.04
-5663.19%
-0.00
-30.54%
-0.00
+82.62%
-0.00
Change In Working Capital
-1.62
-76.53%
-0.92
-212.40%
0.82
-63.41%
2.23
Change In Receivables
-0.02
0.00
—
—
Changes In Account Receivables
-0.02
0.00
—
—
Change In Prepaid Assets
0.12
+23837.10%
-0.00
+99.85%
-0.33
-160.57%
0.54
Change In Payables And Accrued Expense
-1.72
-111.22%
-0.81
-178.06%
1.04
-38.16%
1.69
Change In Payable
-1.72
-111.22%
-0.81
-178.06%
1.04
-38.16%
1.69
Change In Account Payable
-0.88
-8.26%
-0.81
—
—
Change In Other Working Capital
—
-0.10
-202.06%
0.10
+5114.40%
0.00
Investing Cash Flow
-8.42
-38.07%
-6.10
-430.57%
1.85
-73.30%
6.91
Cash Flow From Continuing Investing Activities
-8.42
-38.07%
-6.10
-430.57%
1.85
-73.30%
6.91
Capital Expenditure
-2.01
—
—
—
Net Investment Purchase And Sale
-6.42
-5.15%
-6.10
-430.57%
1.85
-73.30%
6.91
Purchase Of Investment
-19.06
-48.33%
-12.85
+4.48%
-13.45
-178.16%
-4.84
Sale Of Investment
12.65
+87.36%
6.75
-55.88%
15.30
+30.21%
11.75
Net Business Purchase And Sale
—
—
—
0.00
Net Intangibles Purchase And Sale
-2.01
0.00
—
—
Purchase Of Intangibles
-2.01
0.00
—
—
Financing Cash Flow
18.30
+45.62%
12.57
-3.80%
13.07
+135.44%
5.55
Cash Flow From Continuing Financing Activities
18.30
+45.62%
12.57
-3.80%
13.07
+135.44%
5.55
Net Issuance Payments Of Debt
—
—
—
0.00
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
—
0.00
Long Term Debt Issuance
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Short Term Debt Payments
—
—
—
0.00
Net Short Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
0.00
-100.00%
5.05
0.00
-100.00%
5.55
Cash Dividends Paid
-0.08
+94.28%
-1.36
+6.57%
-1.45
0.00
Repurchase Of Capital Stock
0.00
+100.00%
-0.07
+55.93%
-0.17
0.00
Proceeds From Stock Option Exercised
11.73
0.00
—
0.00
Changes In Cash
0.81
+132.45%
-2.51
-229.81%
1.93
+900.36%
0.19
Beginning Cash Position
0.17
-93.54%
2.68
+257.90%
0.75
+34.74%
0.56
End Cash Position
0.99
+470.01%
0.17
-93.54%
2.68
+257.90%
0.75
Free Cash Flow
-11.07
-23.38%
-8.98
+30.85%
-12.98
-5.79%
-12.27
Interest Paid Supplemental Data
0.00
0.00
0.00
-100.00%
0.01
Income Tax Paid Supplemental Data
0.00
0.00
0.00
0.00
Common Stock Issuance
0.00
-100.00%
5.05
0.00
-100.00%
5.55
Issuance Of Capital Stock
6.65
-52.47%
14.00
-4.67%
14.69
+164.61%
5.55
Net Preferred Stock Issuance
6.65
-25.03%
8.88
-38.86%
14.52
0.00
Preferred Stock Dividend Paid
-0.08
+94.28%
-1.36
+6.57%
-1.45
0.00
Preferred Stock Issuance
6.65
-25.64%
8.95
-39.06%
14.69
0.00
Preferred Stock Payments
0.00
+100.00%
-0.07
+55.93%
-0.17
0.00
Sale Of Business
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category